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In vitro toxicity testing in the twenty-first century
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The National Research Council (NRC) article “Toxicity Testing in the 21st Century: A vision and 
A Strategy” (National Research Council, 2007) was written to bring attention to the application 
of scientific advances for use in toxicity tests so that chemicals can be tested in a more time 
and cost efficient manner while providing a more relevant and mechanistic insight into the 
toxic potential of a compound. Development of tools for in vitro toxicity testing constitutes an 
important activity of this vision and contributes to the provision of test systems as well as data 
that are essential for the development of computer modeling tools for, e.g., system biology, 
physiologically based modeling. This article intends to highlight some of the issues that have to 
be addressed in order to make in vitro toxicity testing a reality in the twenty-first century.
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Whether in vitro tests are based on primary cells, immortalized 
(e.g., SV40 transformation) and cancer-derived cell lines, stem cells, 
or reconstituted tissue cultures, it is important to have in vitro sys-
tems that adequately mimic key events of the in vivo mechanisms 
of action triggered in humans upon exposure to a toxic compound. 
Indeed, cells or tissue may no longer exhibit relevant in vivo-like 
functionality with respect to the endpoint and type of compounds 
to be tested. In other words, they may no longer express mechanisms 
that in vivo are required for a compound to be toxic (giving false 
negative responses), or they may express mechanisms and are not 
active in vivo (resulting in false positive responses) in a healthy 
individual. Thus, proper functional characterization of cells, cell 
lines (including stem cells), and tissue is required before initiation 
of test development. There is no need to say that defining whether 
or not a cell-based test reveals adequate in vivo functionality is a 
difficult task requiring solid understanding of the physiological 
mechanisms occurring in humans in vivo and in cells in vitro. It has 
to be stressed also that the definition of in vivo-like functionality 
is dependent on the question (e.g., impact of a compound on an 
endpoint such as cytokine release or key event such as a pathway) 
that the cell assay has to answer.
Since cell functionality in vivo is driven by the microenvironment 
surrounding the cell, as well as by cell–cell interactions, development 
of in vivo-like in vitro tests requires urgently a better understanding 
of the impact of the microenvironment and cell–cell interactions 
on the mechanisms driving cell differentiation, dedifferentiation, 
and responsiveness to, e.g., xenobiotics. This understanding is 
required to boost the development of well-characterized human-
derived proteins (e.g., for establishing defined culture media), cell 
lines and cells (including stem cells), organ cultures, and tissues for 
in vitro modeling of in vivo-relevant toxicological events.
From identiFication oF pathways to key events and 
markers oF toxicity
In vitro toxicity testing should build upon an in-depth under-
standing of the physiological processes related to toxicological 
endpoints, and to find the key pathways and components of these 
human-speciFic methods – the challenges
In vitro toxicity testing should build upon test models that are 
relevant for the species to be protected. Proper test development 
requires well defined test compounds with high quality in vivo data 
(gold standard) and cell systems that mimic in vitro the key events 
that are known to occur in vivo.
Outside the pharmaceutical industry, adequate gold standards 
based upon human data are very rare. Consequently, human cell-based 
tests are often developed against gold standards of animal origin and 
may not reflect events occurring in humans after exposure to a toxic 
compound. One well established example is nickel-induced contact 
dermatitis. When tested on mice, there is no evidence for nickel induc-
ing contact hypersensitivity. However, there is ample evidence provided 
by both in vitro tests based upon human cells as well as human clinical 
data demonstrating that nickel induces contact dermatitis (Schmidt 
et al., 2010). One way to overcome this hurtle is to acquire a solid and 
in-depth understanding of the mode of action and mechanisms of 
action driving a toxic response in humans. Such an understanding may 
provide the confidence that is required to make the leap from animal 
experiments to in vitro human cell-based toxicology for protecting 
humans. Referring to the example of nickel, in-depth mechanistic stud-
ies have demonstrated that species-specific differences in the response 
to nickel are related to differences between the amino acid sequences 
of mouse and human Toll-like receptor 4 (Schmidt et al., 2010).
In general, the majority of the currently available cell-based 
models suffer from a series of limitations (e.g., reduced metabolic 
competence, cancer cells) which future research and development 
need to address (Prieto et al., 2006; Hartung, 2007). The lack of 
a regular supply of human tissue jeopardizes the availability of a 
number of cell-based tests (e.g., liver, lung, brain). An obvious solu-
tion is the use of sustainable human cell lines or human stem cell 
technology. However, both cell types face the issue of in vivo-like 
functionality (or lack thereof). For those tissues where availability is 
a less of a problem (e.g., skin), primary cells are used. An important 
limitation of primary cells is donor-to-donor variability, which in 
many cases affects the reproducibility of the test in question. Also 
here, sustainable cell lines or stem cells are a solution.
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Thus, the new technologies have made it imperative to under-
stand the mechanistic differences in adverse and adaptive responses 
to compound exposure.
Special attention should be given to chemicals to which humans 
are chronically exposed. Indeed, there is a growing concern about 
the impact of doses that cause adaptive responses when these doses 
are imposed on the system for longer periods.
Finally, responses may be modified by adjacent cells and tissues. 
The time line of exposure and responses may also differ. Tools that 
make it possible to address these issues (e.g., inter-connected cell 
culture systems, imaging techniques, interactomics, physiologically 
based pharmacokinetics) have to be implemented.
tools For increasing predictivity
To decrease the number of animals used for in vivo toxicity 
testing, the use toxicogenomics for identifying and/or dissect-
ing the mechanisms of action of a test compound has been 
recommended.
Toxicogenomics can provides a library of generic expression 
profiles for different classes of toxicity that allows the charac-
terization of an unknown compound based upon the profiles 
with which it fits. While genomics is used on a large scale for 
pathway analysis and marker identification, this concept has 
not yet been fully implemented in toxicity testing strategies and 
risk assessment.
Carcinogenicity testing is in this respect an interesting case 
study. The use of toxicogenomics for identifying the mechanisms 
of action of genotoxic and non-genotoxic carcinogens has been 
increasing over the past few years and there are now training 
sets for carcinogens and non-hepatotoxic non-carcinogens. 
The learnings of this case study should be also implemented on 
other toxicological endpoints (Johnson et al., 2004; Van Delft 
et al., 2004).
It can be anticipated that the integration of genomics, pro-
teomics, and metabonomics data obtained from exposed and 
unexposed cellular or animal models, and clinical samples, will 
improve our understanding of the mechanisms of action of a 
test compound significantly (Hanahan and Weinberg, 2000). 
Furthermore, these data will help to establish relevant associa-
tions using newly developed computational technologies (e.g., 
systems biology).
integrated testing strategies
It is anticipated that a more in-depth understanding of the relation 
between toxicity and biological pathways will make it possible to 
prevent animal testing by using a combination of tests that indi-
vidually represent key events of the mechanisms of action of toxicity 
and that allow for assessment of the potential of a test compound to 
affect these key events. In vitro and in silico methods can be used to 
accomplish this. If sufficient scientific justification is provided it 
may be possible to waive an animal test.
When selecting the battery of in vitro and in silico methods 
addressing key steps in the relevant biological pathways, it is 
important to employ standardized and internationally accepted 
tests. Each block should be producing data that are reliable, robust, 
and relevant (the alternative 3R elements) for assessing the  specific 
pathways involved in the responses to toxin exposure. Based upon 
the experiences within the field of carcinogenicity, it is expected 
that the number of relevant pathways is limited to tens to hundreds 
(Johnson et al., 2004; Van Delft et al., 2004). Thus, high through-
put and content screening tests are needed using human-specific 
assays. In this context, the models may not necessarily be derived 
from the target organ, rather should simply demonstrate the pres-
ence of the pathway or mechanism of interest and the effect of a 
chemical upon it.
It may be possible to acquire further insight into human in vivo 
mechanisms and pathways, and to assess the relevance of the in vitro 
identified mechanisms, by implementing tools used by the phar-
maceutical industry in human clinical studies (e.g., micro-dosing 
and tracing studies). A better understanding of the mechanisms 
and pathways involved may in the end allow for data extrapolation 
from a healthy to a diseased state.
There is a general need for markers and marker profiles with 
adequate power to predict toxicity (including potency) and, in 
the case of pharmaceuticals, efficacy. For several diseases (e.g., 
allergy, chronic diseases, cancer), specific clusters of genes have 
been identified and evaluated. Gene-cluster modeling has increased 
our understanding of the mechanisms of action driving the clinical 
conditions, and diagnostic markers have been identified (Gohlke 
et al., 2009). The relevance of these markers for toxicity testing 
remains to be established.  Gene-cluster modeling before and after 
exposure of human-specific in vitro test systems to toxic and non-
toxic compounds has been performed in an effort to identify new 
markers and marker profiles for toxicity. Progress has been made, 
but the resulting markers and marker signatures remain to be opti-
mized and adapted for prediction of a specific endpoint related to 
a specific clinical condition.
deFining adversity
To date, human risk assessment is based upon thresholds defining 
“no effect levels” (chemical and cosmetic industry) or “no adverse 
effect levels” (pharmaceutical industry) in animal studies. Defining 
a threshold for humans based upon data from animal experiments 
has been and still is challenging, and often leads to false positive 
results. From an industrial point of view, a high rate of false positives 
has to be avoided as this leads to the elimination of often promising 
compounds. From the risk assessment point of view, false negative 
results threaten human safety and should be avoided.
The current animal-based perception of “no adverse effect lev-
els” has been challenged by the high sensitivity of the emerging 
techniques (e.g., genomics, proteomics, metabonomics) making it 
possible to detect responses at very low doses of a compound. The 
consequences are very evident in the area of genotoxicity, where 
thus far any effect of a non-pharmaceutical compound on biologi-
cal in vivo systems results in a “no go.” Indeed, the high sensitivity 
has made it possible to detect changes induced by other factors than 
chemical exposure (e.g., changes in nutrient concentrations and 
pH, cell cycle, and aging). In addition, exposure to low dose of a 
chemical will induce detectable changes not leading to the demise 
of the cell per se but causing changes in, e.g., signal pathways to 
counteract the effect of the chemical. These events should not be 
equated to a high dose effect which causes irreversible cell injury.
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retrieve  information as well as reliably repeat the studies in question 
regardless of whether the original work was performed to Good 
Laboratory Praxis (GLP) standards.
It is important to address in a systematic way the factors that are 
critical for assay reproducibility and reliability. An issue often faced 
while performing cell-based tests is intra- and inter- laboratory 
variability in spite of rigorous compliance with the Standard 
Operation Procedure (SOP). The reasons for this variability are 
often undefined but it is generally accepted that the causes include 
the cell cultures, analytical processing, technical error, and differ-
ences in qualitative judgment. Therefore, these parameters should 
be carefully addressed and standardized. Retrospective weight of 
evidence would be one tool for harmonizing how people perform 
specific tests and to assure good quality of the data. This would 
help to identify flaws in the analytical processes, technical error, 
and qualitative judgment. The exploitation by the in vitro testing 
community of emerging nano-biotechnologies facilitating the 
real time monitoring of cellular activity and processes reflecting 
the quality of the cell culture would provide objective tools for 
eliminating variations in the performance of cell-based tests.
aspect (e.g., biological pathway) it is supposed to address. If 
they comply with these elements they can be used in integrated 
testing strategies.
To date there are no existing procedures and guidelines for 
putting together and validating such strategies. Obviously, this 
constitutes a hurdle for the implementation by regulatory agen-
cies (Kinsner-Ovaskainen et al., 2009).
validation, implementation, and acceptance
It is important to keep in mind that in vitro tests do not have fewer 
limitations than in vivo tests. Therefore, proof is needed that a new 
method is equal to or better than an existing in vivo traditional 
model. An added challenge is that since science is moving very 
quickly it is difficult to decide when a test is good enough to be a 
final test for risk assessment.
There is a need to incorporate new thinking into risk assess-
ment. Regulators are receptive to new technologies but concrete 
data (e.g., mechanistic understanding and relevance) are needed 
to support their use. Data documentation should be compre-
hensive, traceable, and make it possible for other investigators to 
